Clinical Trials Browser

INDUSTRY × Neoplasms × Lomustine × Clear all

Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local, Neoplasms, Central Nervous System Neoplasms

NCT03678883 2024-11-07

9-ING-41 in Patients with Advanced Cancers

BreastCNSGastrointestinalGenitourinaryLymphoidOther hematologic neoplasmSarcomaThoracic

Bone Neoplasms, Breast Neoplasms, Glioma, Kidney Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms, Hereditary Sensory and Autonomic Neuropathies, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms, Leukemia-Lymphoma, Adult T-Cell

NCT02765165 2021-07-23

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Phase 1/2 Terminated

26 enrolled 20 charts

CNS

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence

NCT00431561 2013-12-03

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase 2 Completed

141 enrolled

CNS

Astrocytoma, Brain Neoplasms, Camurati-Engelmann Syndrome, Glioblastoma, Neoplasms

NCT00503204 2009-11-25

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

Phase 1 Completed

20 enrolled

CNS

Brain Neoplasms, Glioblastoma, Neoplasms

Clinical Trials

IPAX BrIGHT

9-ING-41 in Patients with Advanced Cancers

Phase 1/2 Study of USL311 +/- Lomustine in Advanced Solid Tumors or Relapsed/Recurrent Glioblastoma Multiforme (GBM)

Phase IIb Clinical Trial With TGF-β2 Antisense Compound AP 12009 for Recurrent or Refractory High-grade Glioma

Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour